The Better Medicare Alliance works to articulate the value of Medicare Advantage and the way it has improved access to care and the right kind of care for millions of beneficiaries, said Allyson Y. Schwartz, president and CEO of the Better Medicare Alliance.
The Better Medicare Alliance works to articulate the value of Medicare Advantage and the way it has improved access to care and the right kind of care for millions of beneficiaries, said Allyson Y. Schwartz, president and CEO of the Better Medicare Alliance and former member of the United States House of Representatives for Pennsylvania, at the Value-Based Insurance Design (VBID) Summit held by the University of Michigan's Center for VBID.
Transcript (slightly modified)
What is the purpose of the Better Medicare Alliance and how do you see value-based insurance design fitting into the work that you do?
We're a coalition of stakeholder organizations—I'm talking about insurers, plans, Medicare Advantage plans, provider groups, advocacy groups, and we have a union. So we're growing a coalition of the various stakeholders, including beneficiaries, who care about Medicare Advantage and maintaining and sustaining the value of Medicare Advantage as an option for them within Medicare. What we do is to really work to articulate the value of Medicare Advantage and the way it has improved access to care and the right kind of care for the 17 million seniors and some are people with disabilities who are covered by Medicare. So about a third of people who have the option of Medicare use it and have chosen Medicare Advantage.
What's exciting about being here at the VBID Summit and talking more about value-based insurance design is that we talk a lot about value-based healthcare. And of course the option of insurance companies being able to offer Medicare Advantage and to combine Part A and B, hospital and physician services, and often Part D, and a variety of enhanced benefits, and to do it in a different way that really speaks to what makes a difference in senior's healthcare. We're talking about the focus on primary care, care management, coordination of care, more integrated care, and of course a focus on chronic disease and working to reduce the progression of disease.
Seniors often have multiple chronic conditions, so this kind of coordinated care, attention to what is the best value rather than looking for care they might be able to get and really not getting the right kind of care can make a really big difference in their lives, in their healthcare, and the ability for the healthcare system, including Medicare, to provide the care and services that Medicare beneficiaries require.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More